AstraZeneca is soon to publish results from its pre-exposure prophylaxis trial about anti-Covid antibodies given IM to people with comorbid states that reduce the immune response from vaccines. Reduced severe symptomatic risk (relative) by 77%.

Dr. Barry Dworkin

Medical Mythbusting Commentary for August 23, 2021

AstraZeneca is soon to publish results from its pre-exposure prophylaxis trial about anti-Covid antibodies given IM to people with comorbid states that reduce the immune response from vaccines. Reduced severe symptomatic risk (relative) by 77%. Play Now | Play in Popup | Download

Source:
COVID-19 Antibody Treatment Reduces Risk Of Symptomatic Cases By 77 Percent

Related posts:

  1. New T-cell test to determine past exposure to SARS-CoV-2 is cool science but not a game changer. It may help answer why some become long-haulers after infection while others do not and it is a starting point for discovery and treatment research.
  2. The development of mRNA vaccine technology has the potential to expand to treat and prevent other diseases akin to the technological spinoffs seen with the Apollo space program.
  3. Antibody helps trigger ovarian cancer cell death
  4. New asthma pathway discovery may lead to new approaches to treatment
Bitnami